Business context and reporting period
Entity and period clarification: The supplied filing is Lianluo Smart Limited’s annual report on Form 20-F for the fiscal year ended December 31, 2017—not a Newegg Commerce, Inc. filing or a quarterly report. The company is a China-focused medical-device and wearable-health business, with an emphasis on sleep-apnea diagnosis and related solutions; it also describes smart-device and ecosystem initiatives. Amounts below are U.S. dollars.
Financial performance and position
| Metric | FY2017 | FY2016, restated |
|---|---|---|
| Continuing-operations revenue | $0.882 million | $13.062 million |
| Gross loss | $0.774 million | $4.117 million |
| Gross margin | -88% | -32% |
| Operating loss | $5.058 million | $9.084 million |
| Net loss attributable to Lianluo Smart | $5.136 million | $9.732 million |
| Net loss per share | $0.30 | $0.93 |
| Cash used in operating activities | $5.409 million | $2.775 million |
At December 31, 2017, cash and cash equivalents were $6.809 million; working capital was $7.152 million; total assets were $15.563 million; and shareholders’ equity was $11.153 million. Current liabilities totaled $2.681 million. Total liabilities were $4.410 million, including a $1.729 million warrant liability and $1.537 million of short-term borrowings. The borrowings were unsecured loans from major shareholder Hangzhou Lianluo Interactive, bearing 5% interest and due in 2018. No long-term borrowings were reported.
Cash declined by $3.983 million during 2017. Investing activities used $1.687 million, including a $1.500 million investment in Guardion Health Sciences; financing activities provided $2.973 million, including related-party borrowing and collection of a share-subscription receivable. No dividends are expected in the foreseeable future.
Changes versus the prior comparable period
- Revenue fell 93% year over year. Management attributed the decline to its strategic shift away from lower-margin sleep-respiratory production and toward developing higher-margin sleep-apnea solutions.
- Gross loss narrowed in dollars, but gross margin worsened to -88% as lower sales did not cover relatively fixed production costs. Management also cited the absence of the $2.45 million inventory write-down recorded in 2016.
- Operating loss narrowed 44%, and net loss attributable to the company fell from $9.732 million to $5.136 million. Selling expenses rose 26% as the company invested in sleep-respiratory marketing; general and administrative expenses declined 24%.
- Operating cash use increased from $2.775 million to $5.409 million, with inventory growth a significant cash-flow factor. Inventory rose to $2.218 million from $0.137 million.
- The 2016 statements were restated for warrant accounting. The company reclassified warrants issued to HLI as derivative liabilities and recorded fair-value changes in earnings. Restated 2016 net loss attributable to the company was $9.732 million versus $10.122 million previously reported; loss per share changed from $0.97 to $0.93. Investors were told not to rely on the previously issued 2016 financial statements.
Outlook, commentary, risks and unusual items
Management described sleep-apnea solutions as a potential future growth driver and reported expanding placements in hospitals and physical-examination centers. It intends to promote use of installed systems and explore opportunities with insurers and partners. The filing provides no quantified revenue, earnings, or cash-flow guidance; management’s margin-improvement and growth statements are forward-looking and uncertain.
- Business and customer risks: More than 99% of sales were made to distributors; two customers represented approximately 56% of 2017 continuing-operations revenue, and three suppliers represented approximately 65% of purchases. Product concentration, distributor dependence, competition and demand forecasting are material risks.
- Regulatory and product risks: The company’s assembly permit was due to expire August 25, 2018, and renewal was in process. Medical-device registrations, product quality, and regulatory changes could affect sales. The company disclosed that it had no product-liability insurance.
- Financial reporting controls: Management concluded that disclosure controls and internal control over financial reporting were ineffective at year-end 2017. The identified material weakness was insufficient qualified accounting staff with U.S. GAAP and SEC-reporting expertise and inadequate review capacity. Remediation was planned; the auditor did not attest to internal controls.
- Related-party and unusual items: HLI provided the year-end loans and is a major shareholder. The company also invested $1.500 million in Guardion Health Sciences; it held 3.23% of Guardion at year-end, while an HLI affiliate also invested. A supplier waived approximately $125,000 owed, recognized as other income.
- Contingencies and other risks: Estimated possible employee severance payments of approximately $663,000 were not accrued because management considered payment unlikely. The filing reports no pending or contemplated legal proceedings expected to have a significant financial effect. PRC currency controls, cross-border cash transfer restrictions, and foreign-exchange movements are additional risks.
Most important facts for investors to verify
- Confirm the issuer and period: this is Lianluo Smart Limited’s FY2017 Form 20-F, not a Newegg filing or a Q4-only report.
- Review the restated 2016 financial statements and warrant-liability accounting, including the related valuation assumptions.
- Assess whether the company can reduce negative gross margins and cash burn while rebuilding revenue; verify the actual sales and utilization of sleep-apnea systems.
- Check the status of the assembly-permit renewal, product registrations, and remediation of the disclosed material weakness in financial controls.
- Evaluate liquidity against 2018 related-party loan maturities, customer and supplier concentration, and the recoverability and valuation of inventory and the Guardion investment.